NCT04531332

Continuous Infusion of Linezolid Versus Intermittent Dosing in the Treatment of Nosocomial Pneumonia

Efficacy and Safety of Continuous Infusion of Linezolid Compared With Intermittent Dosing in Critically Ill Pneumonic Patients

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 169 (estimated)
• Sponsor: October 6 University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The investigator's goal in this study is to determine the clinical efficacy and safety of continuous infusion in comparison with standard intermittent infusion.

Detailed description

Prospective randomized controlled clinical trial on critically ill Pneumonic patients, included two groups, over one year period. The first group will be administered intravenous (IV) linezolid 600mg twice daily. The second group will be prescribed linezolid (IV) 600 mg loading dose followed by 1200 mg by continuous infusion. Both groups will be co-administered intravenous (IV) Meropenem 1g every 8 hours empirically.

Conditions

• Pneumonia

Interventions

Type	Name	Description
DRUG	Continuous infusion Linezolid	Linezolid 600 mg intravenous Loading dose followed by 1200 mg/ day by Continuous infusion ( 50 mg /hr )
DRUG	intermittent dosing linezolid	Linezolid 600 mg intravenous twice daily

Timeline

• Start date: 2019-11-15
• Primary completion: 2021-09-15
• Completion: 2021-09-15
• First posted: 2020-08-28
• Last updated: 2021-09-16

Locations

1 site across 1 country: Egypt